Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pentagalloylglucose (Jiangxi Univ. of Chinese Medicine)
- Development stage
- Unknown
- Lead developer
- Jiangxi University of Traditional Chinese Medicine
01
Overview
pentagalloylglucose (Jiangxi Univ. of Chinese Medicine): sourced facts only. name: "Here, pentagalloylglucose has been identified as a potential dual GSTP1/P-gp inhibitor through virtual screening." [PMID:42623920]; target: "Here, pentagalloylglucose has been identified as a potential dual GSTP1/P-gp inhibitor through virtual screening." [PMID:42623920]; developer: "Research Center for Differentiation and Development of CM Basic Theory, Jiangxi University of Chinese Medicine, Jiangxi Province, China; Jiangxi Province Key Laboratory of CM Etiopathogenisis, China." [PMID:42623920]
02
Targets
GSTP1 (Glutathione S-transferase P)
Beyond the preview
Go deeper on pentagalloylglucose (Jiangxi Univ. of Chinese Medicine).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pentagalloylglucose (Jiangxi Univ. of Chinese Medicine).